Total Payments
$16,336
2024 Payments
$6,218
Companies
74
Transactions
656
Medicare Patients
6,455
Medicare Billing
$1.6M
Payment Breakdown by Category
Food & Beverage$11,879 (72.7%)
Consulting$2,630 (16.1%)
Education$1,146 (7.0%)
Other$681.53 (4.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $11,879 | 613 | 72.7% |
| Consulting Fee | $2,630 | 1 | 16.1% |
| Education | $1,146 | 35 | 7.0% |
| Long term medical supply or device loan | $681.53 | 7 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $3,018 | 14 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,656 | 61 | $0 (2024) |
| PFIZER INC. | $1,054 | 66 | $0 (2024) |
| Janssen Biotech, Inc. | $689.18 | 28 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $686.93 | 33 | $0 (2024) |
| Celgene Corporation | $638.61 | 31 | $0 (2024) |
| Amgen Inc. | $591.68 | 37 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $584.09 | 40 | $0 (2024) |
| Daiichi Sankyo Inc. | $558.92 | 28 | $0 (2024) |
| Genentech USA, Inc. | $553.69 | 32 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $6,218 | 127 | GENZYME CORPORATION ($2,831) |
| 2023 | $2,835 | 128 | Janssen Biotech, Inc. ($247.67) |
| 2022 | $2,146 | 94 | PFIZER INC. ($219.04) |
| 2021 | $1,252 | 68 | Novartis Pharmaceuticals Corporation ($147.19) |
| 2020 | $979.55 | 60 | PFIZER INC. ($138.21) |
| 2019 | $953.46 | 51 | Novartis Pharmaceuticals Corporation ($91.59) |
| 2018 | $823.48 | 46 | Novartis Pharmaceuticals Corporation ($145.58) |
| 2017 | $1,128 | 82 | E.R. Squibb & Sons, L.L.C. ($231.84) |
All Payment Transactions
656 individual payment records from CMS Open Payments — Page 1 of 27
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $19.37 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/09/2024 | Immunocore Limited | KIMMTRAK (Drug) | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Rare Disease | ||||||
| 11/14/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/11/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $30.79 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: Oncology | ||||||
| 11/01/2024 | PharmaEssentia USA Corporation | BESREMI (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $29.35 | General |
| Category: BioOncology | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $11.27 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Agios Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $35.67 | General |
| 10/26/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/25/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $26.83 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $21.69 | General |
| 10/21/2024 | SOBI, INC | DOPTELET (Drug) | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Oncology | ||||||
| 10/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $58.60 | General |
| Category: Oncology | ||||||
| 10/10/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Oncology | ||||||
| 10/07/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.90 | General |
| Category: Oncology | ||||||
| 10/04/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: Oncology | ||||||
| 10/03/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $25.18 | General |
| Category: Oncology | ||||||
| 10/02/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $7.03 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $24.75 | General |
| Category: Oncology | ||||||
| 09/30/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 2,105 | 169,181 | $1.7M | $607,413 |
| 2022 | 28 | 1,563 | 102,126 | $880,828 | $312,770 |
| 2021 | 27 | 1,365 | 88,189 | $735,152 | $293,312 |
| 2020 | 31 | 1,422 | 58,695 | $1.0M | $384,967 |
Total Patients
6,455
Total Services
418,191
Medicare Billing
$1.6M
Procedure Codes
118
All Medicare Procedures & Services
118 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 31 | 11,460 | $343,800 | $211,120 | 61.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 72 | 141,750 | $283,500 | $123,190 | 43.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 336 | 969 | $275,334 | $87,778 | 31.9% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 11 | 480 | $175,200 | $40,228 | 23.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 280 | $175,560 | $26,385 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 165 | 211 | $40,812 | $12,057 | 29.5% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 83 | 237 | $38,868 | $11,037 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 71 | 71 | $33,655 | $10,930 | 32.5% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 15 | 7,540 | $37,700 | $10,337 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 75 | $29,414 | $10,047 | 34.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 355 | 1,182 | $15,366 | $9,929 | 64.6% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 385 | 1,305 | $50,895 | $9,924 | 19.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 69 | 69 | $26,601 | $7,796 | 29.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 28 | 53 | $14,022 | $4,914 | 35.0% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 33 | 417 | $24,603 | $4,721 | 19.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 39 | 43 | $14,678 | $4,380 | 29.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 75 | 392 | $28,224 | $4,070 | 14.4% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 24 | 68 | $19,472 | $3,800 | 19.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 11 | 72 | $22,392 | $3,371 | 15.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 19 | $8,590 | $2,572 | 29.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 18 | 38 | $6,693 | $2,316 | 34.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 19 | 101 | $13,534 | $2,101 | 15.5% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 11 | 93 | $5,301 | $1,416 | 26.7% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 16 | 45 | $5,670 | $1,038 | 18.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 17 | 820 | $31,980 | $680.46 | 2.1% |
About Dr. Ghada Kunter, MD
Dr. Ghada Kunter, MD is a Hematology & Oncology healthcare provider based in Jasper, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2008. The National Provider Identifier (NPI) number assigned to this provider is 1851566202.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ghada Kunter, MD has received a total of $16,336 in payments from pharmaceutical and medical device companies, with $6,218 received in 2024. These payments were reported across 656 transactions from 74 companies. The most common payment nature is "Food and Beverage" ($11,879).
As a Medicare-enrolled provider, Kunter has provided services to 6,455 Medicare beneficiaries, totaling 418,191 services with total Medicare billing of $1.6M. Data is available for 4 years (2020–2023), covering 118 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Jasper, GA
- Active Since 04/28/2008
- Last Updated 04/18/2019
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1851566202
Products in Payments
- SARCLISA (Biological) $2,859
- KISQALI (Drug) $934.35
- IMBRUVICA (Drug) $523.92
- IBRANCE (Drug) $460.65
- OPDIVO (Biological) $453.79
- DARZALEX (Biological) $393.73
- KEYTRUDA (Biological) $334.57
- Enhertu (Drug) $260.68
- INJECTAFER (Drug) $257.74
- ADCETRIS (Biological) $251.73
- DOPTELET (Drug) $240.17
- Pomalyst (Drug) $236.08
- TASIGNA (Drug) $185.74
- XTANDI (Drug) $183.03
- XPOVIO (Drug) $170.64
- TAGRISSO (Drug) $166.75
- JAKAFI (Drug) $162.89
- Lenvima (Drug) $150.64
- LYNPARZA (Drug) $150.03
- Neulasta (Biological) $148.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.